AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation, AutologousBone Marrow TransplantationGraft vs Host DiseaseTransplant Donor SiteTissue DonorsTransplantation ConditioningHematopoietic Stem Cell MobilizationLiving DonorsLeukapheresisGranulocyte Colony-Stimulating FactorHematologic NeoplasmsStem CellsBlood Component RemovalKidney TransplantationHematopoietic Stem CellsAntigens, CD34Stem Cell TransplantationImmunosuppressive AgentsTreatment OutcomeGraft SurvivalMelphalanCombined Modality TherapyCyclophosphamideMultiple MyelomaBusulfanAntineoplastic Combined Chemotherapy ProtocolsCord Blood Stem Cell TransplantationBlood DonorsHistocompatibilityRecurrenceBlood CellsHistocompatibility TestingLymphoma, Non-HodgkinMyeloablative AgonistsCytomegalovirus InfectionsBlood Cell CountRetrospective StudiesTransplantation ChimeraTransplantationEtoposideWhole-Body IrradiationTime FactorsAntineoplastic Agents, AlkylatingRemission InductionThiotepaOpportunistic InfectionsHematopoiesisLeukemiaImmunocompromised HostSurvival RateSalvage TherapyInfectionBone Marrow PurgingDisease-Free SurvivalVidarabineSurvival AnalysisAnemia, AplasticIfosfamideHematologic DiseasesHodgkin DiseaseCyclosporinePlatelet CountTransplantsEmbryonic Stem CellsNeoplasmsFlow CytometryLeukemia, Myeloid, AcuteCytarabineLeukocytes, MononuclearTransplantation, IsogeneicLeukocyte TransfusionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCell SeparationLymphocyte DepletionPOEMS SyndromeAdult Stem CellsFollow-Up StudiesCytomegalovirusLymphomaFatal OutcomeAmyloidosisImmunosuppressionGraft RejectionImmunophenotypingRecombinant ProteinsProspective StudiesAcute DiseaseT-LymphocytesPlatelet TransfusionVincristineImmunomagnetic SeparationBone MarrowFeasibility StudiesBone Marrow CellsLeukocyte CountBone Marrow DiseasesHLA Antigens
TransplantationHSCTEngraftmentHuman leukocyCyclophosphamideGVHDHaploidenticalChemotherapyInfusionLymphocyteRelapseRecipientsAutologousBone Marrow TraPost-transplantLymphocytesHematopoietic cell transplantGraftAdoptiveHealthy donorsSelectively-depletedAntigensClinicalMononuclear cellsDifferentiationDepletionMatched unrelated donorRelated and unrelated donorsCentersChimerismProgenitor-cellImmuneOutcomesApheresisSurvivalAllogeneic bloodProliferationRegimenReceptorUmbilicalEffector T celCytokineAcuteAdultMalignanciesFludarabinePediatricSevereGenetic abnormalitiesAdoptively transferredMobilization of hematopoieticMultipotent2021MarrowPatient's
Transplantation53
HSCT15
  • Although outcomes after HSCT have improved markedly since transplants were first utilized, infection remains an important source of morbidity. (medscape.com)
  • Sequential same donor αβdepleted-HSCT/KT can 1) eliminate the need for lifelong immunosuppression, 2) reduce the need for a 2nd KT, and 3) cure the underlying disease, resulting in improved lives of patients, decreased societal costs and enormous socio-economic benefit to California. (ca.gov)
  • This is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in patients with acquired and inherited bone marrow failure (BMF) syndromes. (sparkcures.com)
  • This response is mediated largely by cytotoxic T lymphocytes (CTL) but it can be employed by natural killers (NK cells) as separate effectors, particularly in T-cell-depleted HLA-haploidentical HSCT. (wikipedia.org)
  • For some forms of hematopoietic malignancies, for example acute myeloid leukemia (AML), the essential cells during HSCT are, beside the donor's T cells, the NK cells, which interact with KIR receptors. (wikipedia.org)
  • For this reason, we conducted a retrospective analysis in order to evaluate the impact of Haplo family donors characteristics on HSCT outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with post-transplant cyclophosphamide (PTCy). (bvsalud.org)
  • In conclusion, donor-related variables significantly influence AML patient outcomes following Haplo-HSCT with PTCy. (bvsalud.org)
  • n = 208 no-LTV), undergoing HSCT with post-transplant cyclophosphamide (PTCy) and calcineurin inhibitor- (CNI) free graft-versus-host-disease (GvHD) prophylaxis. (bvsalud.org)
  • Overall, in our study the use of LTV was associated with a slight improvement of B-cell and NK-cells reconstitution, with only minor impact on T-cell subsets, giving new insights on polyclonal IR for HSCT recipients in the LTV era. (bvsalud.org)
  • METHODS: We conducted a retrospective analysis on 14 patients with MF who underwent HSCT with SI from any donor source at our center between June 2016 and March 2021. (bvsalud.org)
  • Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia. (chop.edu)
  • Unrelated donor (URD) hematopoietic stem cell transplant (HSCT) is associated with an increased risk of severe graft-versus-host disease (GVHD). (chop.edu)
  • Therefore, we modeled allo-HSCT in ART-suppressed simian-human immunodeficiency virus (SHIV)-infected Mauritian cynomolgus macaques (MCMs) to illuminate factors contributing to transplant-induced viral reservoir decay. (wisc.edu)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
Engraftment9
  • with the establishment of a full donor lymphoid engraftment, we eliminate the risk of kidney rejection and the need of lifelong immunosuppression. (ca.gov)
  • NK cells are within the first cells to repopulate host's bone marrow which means they play important role in the transplant engraftment. (wikipedia.org)
  • However, HLA-identical sibling stem cell infusions in ADA-SCID result in some donor stem cell engraftment and long-term thymopoiesis. (frontiersin.org)
  • There was 93% donor T-lymphocytes, 20% donor B-lymphocytes, and 5% donor myeloid cells, indicative of some donor stem cell engraftment. (frontiersin.org)
  • 12 months after first HCT with acceptable rates of GVHD and donor engraftment. (biomedcentral.com)
  • To improve isolation and modification of HSPCs as well as their engraftment in the transplant recipients, the authors modified recommendations from the international FA Gene Therapy Working Group. (fredhutch.org)
  • As explained by Dr. Adair, "our previous work and in research done by others in the field, there has been a clear need to correct the FA defect to elicit engraftment of FA cells. (fredhutch.org)
  • We hope that this study will demonstrate the ability to not only isolate more of this limited stem cell pool from FA patients, but will also render these fewer cells more fit for engraftment. (fredhutch.org)
  • Engraftment took place on day 49, 14 days after the second transplant. (cdc.gov)
Human leukocy6
  • Allogeneic transplants are further categorized by the degree of human leukocyte antigen (HLA) match between the donor and recipient. (medscape.com)
  • Risk factors for development of acute graft-versus-host disease depend upon the type of graft you're using-whether it's from an HLA [human leukocyte antigen]-matched sibling versus an HLA-matched unrelated donor, or if you're using a partially matched donor. (targetedonc.com)
  • Antibodies directed against white blood cell (WBC) human leukocyte antigen (HLA) in otherwise compatible donor blood are one possible cause. (merckmanuals.com)
  • Avoiding transfusions from family members is important because of possible sensitization against non-HLA (human leukocyte antigen) tissue antigens of potential donors. (medscape.com)
  • However, in the absence of human leukocyte antigen (HLA)-compatible donors, no other curative treatment options are available, and therefore, new treatment strategies, such as gene therapy, should be explored. (biomedcentral.com)
  • We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. (biomedcentral.com)
Cyclophosphamide4
  • All patients received a conditioning backbone based on treosulfan and fludarabine, with post-transplant cyclophosphamide (PTCy) and sirolimus as graft-versus-host disease (GvHD) prophylaxis. (bvsalud.org)
  • Using mice models, Dr. Fitzhugh et al showed for the first time that sirolimus and post-transplant cyclophosphamide work synergistically to induce tolerance (Fitzhugh CD et al. (nih.gov)
  • Patients in the first cohort did not receive post-transplant (PT)-cyclophosphamide (Cy) and 3 patients were transplanted. (nih.gov)
  • Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (stanford.edu)
GVHD13
  • The greater the mismatch between donor and recipient, the higher the risk of graft versus host disease (GVHD). (medscape.com)
  • In GVHD, the donated stem cells view the recipient cells as foreign and attack recipient cells. (medscape.com)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
  • CD4+CD25+ regulatory T cells (Treg) can be used to suppress GvHD without loss of beneficial GvT effect. (wikipedia.org)
  • When transplanting T-cell depleted stem cell transplant, GvHD can be partially prevented, but in the same time the GvL effect is also reduced, because T-cells play an important role in both of those effects. (wikipedia.org)
  • When transplanting HSC during AML, T-cells are usually selectively depleted to prevent GvHD while NK cells help with the GvL effect which prevent leukemia relapse. (wikipedia.org)
  • T-cell depletion is an approach that enhances procedure tolerability by reducing acute and chronic GVHD related morbidity and mortality. (biomedcentral.com)
  • We have employed in vivo T-cell depletion with alemtuzumab for over a decade at the University of Chicago and confirmed lower rates of acute and chronic GVHD with similar overall survival to T cell repleted HCT [ 10 ]. (biomedcentral.com)
  • The blood products should, if possible, undergo leukocyte reduction to prevent alloimmunization and CMV transmission and should be irradiated to prevent transfusion-associated graft versus host disease (GVHD) in HCT candidates. (medscape.com)
  • Neither pre-transplant clinical characteristics nor transplant characteristics are reliably predictive of GvHD outcomes. (cryostem.org)
  • Discovery and availability of biomarkers suitable for screening high risk patients using early, non-invasive, blood tests specific for GvHD-therapy resistance would significantly aid in the management of patients with this disease and would allow for rational drug development and drug approval by regulatory authorities. (cryostem.org)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
Haploidentical3
  • 1. By using haploidentical parents, we will expand the number of potential living donors, and 2. (ca.gov)
  • This was developed by the Johns Hopkins University group and has been demonstrated to permit the use of haploidentical stem cell grafts. (targetedonc.com)
  • Outcome data with TCRαβ/CD19 depletion generally describe haploidentical donors, with relatively few URDs. (chop.edu)
Chemotherapy12
  • In view of the disseminated CMV infection, the decision was made to infuse stem cells without any pre-conditioning chemotherapy. (frontiersin.org)
  • The treatment options for disease relapse after HCT include withdrawal of immune suppression, chemotherapy, second allogeneic transplant, cytokine and adoptive cell therapy and donor lymphocyte infusion [ 1 ]. (biomedcentral.com)
  • One of the reasons for this is the lack of repopulating cells obtained in prior methods of isolation, such as CD34 enrichment, and the other major reason for this is the systemic toxicity of conditioning regimens which include DNA-damaging chemotherapy. (fredhutch.org)
  • This could re-open the door for up-and-coming, non-chemotherapy based conditioning regimens currently under study to improve the therapeutic potential of gene therapy for the many FA patients who do not have suitable allogeneic donors available. (fredhutch.org)
  • This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. (stanford.edu)
  • Giving CD19/CD22-CAR T cells and chemotherapy may work better in treating children or young adults with B acute lymphoblastic leukemia. (stanford.edu)
  • After receiving an autologous stem cell transplant (SCT), she experienced a relapse of disease and was enrolled in an experimental protocol of immunoablative chemotherapy, followed by hematopoietic SCT at the National Institutes of Health Clinical Center in Bethesda, Maryland ( www.ClinicalTrials.gov identifier NCT00520130). (cdc.gov)
  • They can also be used for increasing white blood cell survival and for chemotherapy. (justia.com)
  • After harvesting, the patient is given high dose chemotherapy or radiotherapy and the bone marrow function is reconstituted by infusion of the cells harvested earlier. (justia.com)
  • The use of high-dosage chemotherapy or radiotherapy for bone marrow ablation requires subsequent incorporation of hematopoietic stem cells into the patient, in which case prior harvesting of such cells is required. (justia.com)
  • As primary endpoint, the event-free survival was compared to a cohort of 55 patients who completed chemotherapy and were in first complete remission but did not receive NK cells. (biomedcentral.com)
  • Patients may alternatively receive lympho-depleting chemotherapy followed by adoptive transfer of purified NK cells from an alloreactive donor, resulting in homeostatic lymphocyte proliferation with transient donor NK cell expansion in recipients [ 7 ]. (biomedcentral.com)
Infusion4
  • The harvested stem cells are processed before infusion into the recipient. (medscape.com)
  • Quality control testing is essential to ensure the CAR-T cell product meets established specifications for manufacturing release and patient infusion. (bdbiosciences.com)
  • The methotrexate is usually given on days 1, 3, 6, and 11 following the stem cell infusion. (targetedonc.com)
  • She received a matched sibling donor unconditioned stem cell infusion at 16 months of age. (frontiersin.org)
Lymphocyte3
  • At 4 years of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte and natural killer cell numbers. (frontiersin.org)
  • These molecular defects interfere with lymphocyte development and function, blocking the differentiation and proliferation of T cells and, in some types, of B cells and NK cells. (medscape.com)
  • Beyond this basic grouping, SCID may be categorized according to phenotypic lymphocyte profiles that include both B-cell status (B + or B - ) and NK-cell status (NK + or NK - ) in addition to T-cell status (T - , because there is always a T-cell deficiency in SCID). (medscape.com)
Relapse6
  • Relapsed patients who previously met hematologic criteria for severe aplastic anemia do not have to meet these hematologic criteria for severe aplastic anemia at time of relapse to be eligible for transplant. (sparkcures.com)
  • Donor´s age and female donor to male recipient combination also affected non-relapse mortality, leukemia-free survival and overall survival. (bvsalud.org)
  • Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT. (biomedcentral.com)
  • Although this is presumed to be a curative strategy, many patients relapse after transplant, prompting us to examine various ways that we can improve outcomes. (sagepub.com)
  • The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant. (sagepub.com)
  • Early features such as stem cell properties has long been proven to be linked to early relapse in AML. (ghrnet.org)
Recipients6
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
  • The median age of donors was 37 years (range, 8-71), 820 (37%) were females, including 458 (21%) who were used for male recipients. (bvsalud.org)
  • The use of PB, older donor´s age and female donors to male recipients negatively affected GRFS. (bvsalud.org)
  • When possible, younger donors and male donors for male recipients should be prioritized. (bvsalud.org)
  • Whether the alternated microbiota in the gut contribute to the risk of allograft rejection (AR) and pulmonary infection (PI) in the setting of lung transplant recipients (LTRs) remains unexplored. (nature.com)
  • The inhibitory KIRs 2DL1 (CD158a), 2DL2/3 (CD158b), and 3DL1 (CD158e1) are such surface receptors and allow adoptively transferred donor NK cells to exert potent antileukemic effects if the cognate HLA class I ligands are absent in the recipients [ 3 ]. (biomedcentral.com)
Autologous1
  • Expanded natural killer cells killed both allogeneic and autologous primary myeloma cells avidly via a perforin-mediated mechanism in which the activating receptor NKG2D, natural cytotoxicity receptors, and DNAX-accessory molecule-1 played a central role. (haematologica.org)
Bone Marrow Tra2
Post-transplant6
  • The post-transplant course was uneventful. (frontiersin.org)
  • With a median post-transplant follow-up of 25 months, 6 patients remain in CR with full-donor chimerism, 3 patients died due to NRM. (bvsalud.org)
  • One of the 3 patients engrafted but lost the graft at 7 months post-transplant. (nih.gov)
  • Based on the three patients losing their grafts, stopping rules were met and the study moved to the 2nd cohort where 1 dose of Cy was given at 50mg/kg on day 3 post-transplant. (nih.gov)
  • When stopping rules were again met, the study advanced to the third cohort which included 100mg/kg Cy in divided doses on days 3 and 4 post-transplant. (nih.gov)
  • However, the mechanism(s) responsible for these post-transplant viral reservoir declines are not fully understood. (wisc.edu)
Lymphocytes2
  • The graft contains donor T cells (T lymphocytes) that can be beneficial for the recipient by eliminating residual malignant cells. (wikipedia.org)
  • To limit loss of CD34 + cells, the procedure was modified to remove T and B lymphocytes, monocytes and granulocytes from bone marrow or mobilized peripheral blood leukapharesis cell products (ie. (fredhutch.org)
Hematopoietic cell transplant2
  • Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. (sagepub.com)
  • The National Marrow Donor Program ® (NMDP)/Be The Match ® today announced the launch of a new cryopreservation service, Be The Match BioBank, aimed at providing hematopoietic cell transplant patients, allogeneic blood stem cell donors and physicians a predictable path to transplant. (biobanking.com)
Graft7
  • However, T-cell depletion is associated with higher rates of graft rejection and increased vulnerability to viral and fungal infections while the T-cell population is diminished. (medscape.com)
  • If you're doing an in vivo or ex vivo T-cell depletion, the incidence of graft-versus-host disease is going to be lower than when you do a T-cell-replete, for which you leave the T cells in the graft, or you don't try to significantly remove them afterward using monoclonal antibodies targeting T cells. (targetedonc.com)
  • The incidence of acute graft-versus-host disease is much higher when associated with a female donor. (targetedonc.com)
  • Therefore, the immune cells that are passively transferred in the stem cell graft are more primed against these minor histocompatibility antigens that are known to be associated with the development of acute graft-versus-host disease. (targetedonc.com)
  • The other major way to prevent graft-versus-host disease is through T-cell depletion, and that can be ex vivo, where the graft, before it's infused, goes through a process, usually through a selection column to remove T cells from the graft. (targetedonc.com)
  • It could also be due to supporting cells in the graft, which are normally excluded when CD34 + cells are directly enriched. (fredhutch.org)
  • 00:03:11.16 And what those can do, if you do a transplant from a pig to an old-world primate, 00:03:18.28 is they can immediately bind to the endothelial cells at the graft, fix complement, and cause 00:03:25.15 hyperacute rejection, or a more delayed form of rejection called delayed xenograft rejection. (ibiology.org)
Adoptive4
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
  • The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. (stanford.edu)
  • Adoptive therapies with genetically modified somatic T cells rendered HIV resistance have shown promise for AIDS therapy. (wisc.edu)
  • The adoptive transfer and cytotoxic assay against principal cultured hepatocytes verified the function of Compact disc11b+ Kupffer cells in CCl4-induced hepatitis. (enmd-2076.com)
Healthy donors2
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • The aim of this study was to investigate the influence of MSCs on the phenotype, cytokine profile, and functionality of naive and non-naive CD4 + T-cells from healthy donors (HD) and patients with autoimmune arthritis under Th17-cytokine polarizing conditions in an explorative way using a transwell system prohibiting any cell-cell-contact. (biomedcentral.com)
Selectively-depleted4
  • Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients. (knowcancer.com)
  • OUTLINE: This is a dose-escalation study of LMB-2 immunotoxin-treated, selectively-depleted donor T cells. (knowcancer.com)
  • LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
Antigens4
  • 1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)
  • The biology of GvT response is still not fully understood but it is probable that the reaction with polymorphic minor histocompatibility antigens expressed either specifically on hematopoietic cells or more widely on a number of tissue cells or tumor-associated antigens is involved. (wikipedia.org)
  • AHTR usually results from recipient plasma antibodies to donor RBC antigens. (merckmanuals.com)
  • Antibodies against blood group antigens other than ABO can also cause AHTR. (merckmanuals.com)
Clinical11
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
  • Primary interests include clinical trials design and the design and analysis of biomarker and imaging studies especially in the areas of GI cancer, lymphoma, melanoma, transplant and cancer immunotherapy. (dukecancerinstitute.org)
  • The second presentation was by Dr. Courtney Fitzhugh, M.D , Lasker Clinical Research Scholar, Laboratory of Early Sickle Mortality Prevention on the NIH Experience in Nonmyeloablative Allogeneic Transplant for SCD. (nih.gov)
  • In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. (stanford.edu)
  • Microsporidium detected in clinical specimens from a stem cell transplant patient who had undergone substantial immunosuppression. (cdc.gov)
  • Cord blood (CB) mononuclear cells (MNC) are being tested in clinical trials to treat hypoxic-ischemic (HI) brain injuries. (biorxiv.org)
  • Determining which cell types in CB-MNC enhance brain tissue repair, and the mechanisms by which they do so, will optimize decisions on dosing, route of administration, treatment frequency, and other critical clinical and regulatory parameters. (biorxiv.org)
  • Clinical manifestations of PNH occur when a HSC clone carrying somatic PIGA mutations acquires a growth advantage and differentiates, generating mature blood cells that are deficient of GPI-anchored proteins. (medscape.com)
  • The name of the disorder is a descriptive term for the clinical consequence of red blood cell (RBC) breakdown with release of hemoglobin into the urine, which manifests most prominently as dark-colored urine in the morning (see image below). (medscape.com)
Mononuclear cells2
  • T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. (knowcancer.com)
  • The immunohistochemical evaluation from the liver organ and the stream cytometry from the liver organ mononuclear cells demonstrated that clodronate liposome (c-lipo) treatment significantly reduced the spindle-shaped F4/80+ or Compact disc68+ cells, as the oval-shaped F4/80+ Compact disc11b+ cells elevated. (enmd-2076.com)
Differentiation14
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • These primitive cells undergo division and differentiation to form the various peripheral blood cells. (nationalacademies.org)
  • Sequential rounds of division and differentiation give rise to an enormous amplification of cell numbers, necessary for the production of mature blood cells. (justia.com)
  • This process of division and differentiation is subject to regulation at many levels to control cell production. (justia.com)
  • Human bmMSCs were described in the late nineties as well [ 6 ] and at the same time a breakthrough study investigated the expression of typical cell surface markers and the proliferation and differentiation properties of human MSCs in more detail [ 7 ]. (hindawi.com)
  • They display differentiation capacities and therefore qualify as multipotent progenitor cells (Figure 1 ). (hindawi.com)
  • Overview on self-renewal or differentiation of stem cells in their respective stem cell niche. (hindawi.com)
  • In vivo differentiation to cells from all three germlines was tested using a teratoma assay. (biomedcentral.com)
  • In vitro differentiation of GS-2 iPSCs into hematopoietic stem and progenitor cells was done using Op9 feeder layers and specified media. (biomedcentral.com)
  • Differentiation capacity into cells from all three germ layers was confirmed using the teratoma assay. (biomedcentral.com)
  • In isolated naive CD4 + T-cells from HD and patients, MSCs suppressed the differentiation of naive towards an effector phenotype while memory and naive cells showed higher percentages in culture with MSCs. (biomedcentral.com)
  • The results of the study indicate significant immunomodulatory properties of MSCs, as under Th17-polarizing conditions MSCs are still able to control T-cell differentiation and proinflammatory cytokine production in both HD and patients with autoimmune arthritis. (biomedcentral.com)
  • Mesenchymal stem cells (MSCs) are multipotent adult stem (or stromal) cells with the capacity of self-renewal and differentiation potential towards several mesodermal linages such as osteogenic, chondrogenic and adipogenic differentiation (more citations) [ 1 ]. (biomedcentral.com)
  • In the presence of TGF-β, IL-9 may induce differentiation of naive CD4 + T-cells towards Th17 cells, while IL-9 also affects thymus-derived natural Tregs (nTregs) and enhances their suppressive function in vitro [ 26 ]. (biomedcentral.com)
Depletion5
  • This method of lineage depletion rather than cell enrichment limits CD34 + cell loss and manipulation. (fredhutch.org)
  • According to Dr. Adair, "cells isolated by lineage depletion have lightly better output in the mouse xenograft model. (fredhutch.org)
  • This could be due to the lineage depletion process being more gentle on the CD34 + cells since it is an indirect enrichment rather than a direct enrichment. (fredhutch.org)
  • The new protocol involving lineage depletion allows indirect isolation of the CD34+ cells in the negative fraction while the cells that are not of interest are retained by the beads in the positive fraction. (fredhutch.org)
  • mouse and cell depletion tests demonstrated that NKT cells and NK cells weren't mixed up in hepatic damage. (enmd-2076.com)
Matched unrelated donor1
  • Is a matched unrelated donor search needed for all allogeneic transplant candidates? (cdc.gov)
Related and unrelated donors1
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
Centers5
  • A prospective multicenter cohort of LTRs was identified in the four lung transplant centers. (nature.com)
  • Through Be The Match BioBank, transplant centers can access cryopreservation and storage services for patient-directed donor products at no cost to the patient, donor or transplant center. (biobanking.com)
  • Transplant centers have no financial risk to using Be The Match BioBank. (biobanking.com)
  • Transplant centers are not charged for donor workup and procurement until after the cryopreserved product has shipped from Be The Match BioBank to the center. (biobanking.com)
  • By offering flexibility in the donation date to donors, we can increase donor availability and provide transplant centers with the donor they requested more often. (biobanking.com)
Chimerism2
  • Split mixed donor chimerism has corrected the immunological defect. (frontiersin.org)
  • Purified, unmanipulated NK cells were infused on Day 0, and NK cell chimerism and phenotyping from peripheral blood were performed on Days 7, 14, 21, and 28. (biomedcentral.com)
Progenitor-cell2
  • The present invention relates generally to improved methods and pharmaceutical compositions for mobilizing hematopoietic stem and progenitor cell from bone marrow into peripheral blood by administration of at least one inhibitor of a GTPase, such as Rac1 and/or Rac2 GTPase. (justia.com)
  • The various mature blood cell types are all ultimately derived from a single class of progenitor cell known as hematopoietic stem cells. (justia.com)
Immune10
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • As a consequence, blood cell counts are very low in patients and the immune system is severely weakened. (fredhutch.org)
  • A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. (stanford.edu)
  • By the time the product is collected, patients have started a conditioning regimen that depletes their immune system, making them vulnerable to life-threatening infections. (biobanking.com)
  • With the amount of flight cancellations, border crossing restrictions and concerns about donor exposure to COVID-19, we couldn't take the risk that a patient with a depleted immune system wouldn't receive their product on time. (biobanking.com)
  • Griscelli syndrome type 2 (GS-2) is a rare, autosomal recessive immune deficiency syndrome caused by a mutation in the RAB27A gene, which results in the absence of a protein involved in vesicle trafficking and consequent loss of function of in particular cytotoxic T and NK cells. (biomedcentral.com)
  • First, we are interested in Epstein Barr Virus-mediated mechanisms of immune evasion with particular emphasis on pathways that promote survival and proliferation of EBV B cell lymphomas, the characterization of the human T cell and NK cell response to EBV and the identification of novel therapeutics for treatment of EBV B cell lymphomas. (stanford.edu)
  • However, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to Epstein-Barr virus (EBV). (stanford.edu)
  • It really is today generally accepted which the livers of mice and human beings contain types of innate immune system cells [11]C[13]. (enmd-2076.com)
  • As a result, these liver organ immune system cells, including B cells and their cytokines, mainly become innate immune effectors against tumors and infections simply by their T helper-1 immune response in the liver organ. (enmd-2076.com)
Outcomes4
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • Multivariable analysis identified certain donor-related risk factors with a detrimental impact on transplant outcomes. (bvsalud.org)
  • Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. (cdc.gov)
  • 12 months = 0) was generated as an approach to classify patients into different risk categories in the purpose to provide guidance to the transplant physician to inform the outcomes to potential patients undergoing 2nd HCT. (biomedcentral.com)
Apheresis2
  • Other services offered by the Department of Transfusion Medicine (Blood Bank) include Apheresis, Plasmapheresis, and Leukapheresis & Peripheral Stem Cell Harvest. (nanavatimaxhospital.org)
  • Typically, allogeneic donor products are collected from a donor and transported fresh from the apheresis or marrow collection center to the transplant center where the product is immediately infused. (biobanking.com)
Survival1
  • Opinions are embraced and defended, but transfusion of red blood cells has not reliably demonstrated increased survival, other than in 2 specific populations, as follows: (1) those with active hemorrhage, and (2) those with active cardiac ischemia. (medscape.com)
Allogeneic blood1
  • Technology making the transfusion of allogeneic blood products feasible includes Karl Landsteiner's landmark identification of the human blood groups A, B, and O in 1901. (medscape.com)
Proliferation1
Regimen1
  • The bone marrow did not reconstitute, and 35 days after the initial transplant, the patient received a second SCT from the same donor after a conditioning regimen with antithymocyte globulin. (cdc.gov)
Receptor3
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • The mucosa-associated invariant T (MAIT) cells are innate-like T cells with restricted T cell receptor (TCR) usage, which are preferentially localized in mucosal tissues (liver, lung and gut) and respond to microbial infection by rapidly producing cytokines and cytotoxic effectors. (cryostem.org)
  • [ 5 ] Ideally, SCID can be detected in a newborn before the onset of infections, with one well-documented example by screening of T-cell-receptor excision circles. (medscape.com)
Umbilical3
  • The stem cell source may be bone marrow, peripheral blood, or umbilical cord blood. (medscape.com)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • Mononuclear cell (MNC) prepared from human umbilical cord blood (CB) are candidate therapeutics for treating hypoxic-ischemic (HI) brain injuries. (biorxiv.org)
Effector T cel3
  • The fourth generation of CAR-T design attempts to deliver cytokines to modulate the tumor microenvironment either by activating host effector T cells or hampering host suppressors and reinforcing memory T cells. (bdbiosciences.com)
  • To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. (stanford.edu)
  • In patients, MSCs significantly decreased the proportion of IL-9 and IL-17 producing effector T-cells. (biomedcentral.com)
Cytokine5
  • These experimental cytokine-producing CAR-Ts, called T cells redirected for universal cytokine killing (TRUCKs), can deliver a variety of cytokines, such as IL-12, IL-15, IL-18 or IL-21. (bdbiosciences.com)
  • The importance of proinflammatory T-cells and their cytokine production in patients with autoimmune arthritis has been widely described. (biomedcentral.com)
  • Magnetically isolated naive and non-naive CD4 + T-cells were stimulated under Th17-polarizing proinflammatory cytokine conditions in presence and absence of bone marrow derived mesenchymal stromal cells (MSCs). (biomedcentral.com)
  • In certain circumstances, MAIT cells are also able to produce IL-22, a cytokine involved in gut epithelial protection during inflammatory intestinal damage. (cryostem.org)
  • phagocytic and ROS making capacity, and Compact disc11b+ Kupffer cells with cytokine-producing capability. (enmd-2076.com)
Acute2
  • Acute Kidney Injury (AKI) Acute kidney injury is a rapid decrease in renal function over days to weeks, causing an accumulation of nitrogenous products in the blood (azotemia) with or without reduction in amount of urine. (merckmanuals.com)
  • The CD11b+ Kupffer cells producing TNF and FasL play a pivotal role in CCl4-induced acute hepatic injury thus. (enmd-2076.com)
Adult2
  • No HLA-matched (10/10 or 9/10) sibling donor or unrelated donor available NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. (knowcancer.com)
  • To explore these mechanisms further, we exposed mouse brain organotypic slice cultures to oxygen and glucose deprivation (OGD) and then treated the brain slices with cells from CB or adult peripheral blood (PB). (biorxiv.org)
Malignancies1
  • Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)
Fludarabine1
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
Pediatric1
  • [ 5 ] The Pediatric Haemato-Oncology Italian Association recommends HCT from a matched sibling donor for severe aplastic anemia, and if a matched donor is not available, options include immunosuppressive therapy or unrelated donor HCT. (medscape.com)
Severe5
  • Severe allograft rejection (AR) and pulmonary infection (PI) are the most common complications within 1 year after the transplant. (nature.com)
  • Hemolysis is most common and most severe when incompatible donor RBCs are hemolyzed by antibodies in the recipient's plasma. (merckmanuals.com)
  • Once the insulin resistance becomes too severe the pancreas can not keep up, and blood sugar levels begin to rise. (virtualmedstudent.com)
  • If blood sugar levels become ridiculously high severe complications, and potentially death can result. (virtualmedstudent.com)
  • It is the prototype of the primary immunodeficiency diseases and is caused by numerous molecular defects that lead to severe compromise in the number and function of T cells, B cells, and occasionally natural killer (NK) cells. (medscape.com)
Genetic abnormalities1
  • Patient related factors such as age, performance status, co-morbidities and AML-related factors such as white blood count, transformation from MDS , therapy-related AML, genetic abnormalities all influence patient's treatment outcome (reviewed in Dohner et al[3], 2010). (ghrnet.org)
Adoptively transferred1
  • These mice are devoid of endogenous natural killer and T-cell activity and were used to determine whether adoptively transferred expanded natural killer cells could inhibit myeloma growth and myeloma-associated bone destruction. (haematologica.org)
Mobilization of hematopoietic2
  • Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population. (cdc.gov)
  • In such procedures, patients undergo successive treatments with cell mobilization agents to cause mobilization of hematopoietic progenitor cells from the bone marrow to the peripheral circulation for harvesting. (justia.com)
Multipotent2
20213
Marrow18
  • Fanconi anemia (FA) is an inherited disorder affecting DNA repair in hematopoietic (blood) stem and progenitor cells (HSPCs) from the bone marrow. (fredhutch.org)
  • However, the low frequency of CD34 + cells in FA patients limits the numbers of HSPCs that can be obtained by direct enrichment of CD34 + cells from the bone marrow. (fredhutch.org)
  • use of mobilization drugs to decrease HSPC retention in the bone marrow and allow their mobilization to the peripheral blood). (fredhutch.org)
  • When tested on healthy donor bone marrow cells, the lineage depleted cells and CD34 + -enriched cells were transduced with similar efficiencies by the FANCA-carrying viral vector. (fredhutch.org)
  • Bone marrow or mobilized leukapharesis can be used as sources of CD34+ hematopoietic stem cells. (fredhutch.org)
  • Improved methods and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as Rac1 and Rac2 alone or in combination. (justia.com)
  • Stem cells represent a very small percentage of bone marrow cells, and are normally quiescent. (justia.com)
  • These therapies decrease a patient's white blood cell counts, suppress bone marrow hematopoietic activity, and increase the patient's risk of infection and/or hemorrhage. (justia.com)
  • Current treatments to manage the problems that result from prolonged bone marrow suppression include the reinfusion of a patient's own previously harvested hematopoietic stem and progenitor cells. (justia.com)
  • The success of treatment crucially depends on the mobilization of the bone marrow stem cells, the subsequent return of which permits the patient to achieve reconstitution of a functioning hematopoietic system. (justia.com)
  • However, transplanting other than hematopoietic stem and progenitor cells is still limited to a few applications, and it mainly applies to mesenchymal stromal cells (MSCs) isolated from bone marrow. (hindawi.com)
  • Recently, MSCs isolated from bone marrow (bmMSCs) were shown to be a blend of distinct cells and MSCs isolated from different tissues show besides some common features also some significant differences. (hindawi.com)
  • The MSCs have been described for the first time as colony forming fibroblasts (CFU-F), a rare population of cells residing in the bone marrow of guinea-pigs or mice [ 1 , 2 ]. (hindawi.com)
  • Nowadays, experts agree that MSCs may generate upon appropriate stimulation quite different mature cells including osteoblasts, chondrocytes, tenocytes, adipocytes, smooth muscle cells, and stromal cells of the bone marrow [ 9 ]. (hindawi.com)
  • A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets. (jax.org)
  • Through Be The Match BioBank, donors can donate bone marrow or peripheral blood stem cells for an intended patient on a timeline that is convenient for the donor. (biobanking.com)
  • The principal studies used to establish the diagnosis of PNH are flow cytometry of peripheral blood and bone marrow analysis. (medscape.com)
  • Oddly enough, the serum MCP-1 Metoclopramide HCl level elevated and peaked at six h after c-lipo pretreatment quickly, suggesting which the MCP-1 made by c-lipo-phagocytized Compact disc68+ Kupffer cells Metoclopramide HCl may recruit Compact disc11b+ macrophages in the periphery and bone tissue marrow. (enmd-2076.com)
Patient's3
  • The remainder of the blood product and clotted and anticoagulated samples of the patient's blood should be sent to the blood bank for investigation. (merckmanuals.com)
  • Be The Match BioBank reduces the risk that obstacles such as donor availability, patient insurance issues or changes in a patient's treatment status will put a patient's transplant in jeopardy. (biobanking.com)
  • In addition, the donation will not be impacted if a patient's transplant is delayed. (biobanking.com)